[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hereditary-pancreatitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hereditary-pancreatitis":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,57,81,111],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":33,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100120158","collecting-medical-information-and-tissue-samples-from-patients-with-pancreatic-cancer-or-other-pancreatic-disorders-100120158",false,"NCT00830557","Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders","Biospecimen Resource for Pancreas Disease, a Data & Tissue Bank (Also Known as a Bio-repository, Bio-bank, Data & Tissue Database, Data & Tissue Registry, Etc.) to Help Advance Research in Pancreas Disease","* Known or suspected pancreas disease including:\n\n  * pancreas adenocarcinoma\n  * islet cell cancer\n  * pancreatic cysts\n  * pancreatitis (hereditary, acute, or chronic)\n* Next of kin of deceased participant who did not complete participation before passing away\n\nExclusion Criteria:\n\n* Under the age of 18\n* Unable to provide informed consent\n* Prison inmates","ALL","18 Years",{"count":19,"type":20},20000,"ESTIMATED","1 Year","OBSERVATIONAL","RATIONALE: Gathering medical information and collecting and storing samples of blood and tissue to test in the laboratory may help doctors develop better ways to screen people at risk for pancreatic cancer or other pancreatic disorders in the future.\n\nPURPOSE: This clinical trial is collecting medical information and tissue samples from patients with pancreatic cancer or other pancreatic disorders.",[25,26,27,28,29,30,31,32],"Islet Cell Tumor","Pancreatic Cancer","Pancreatic Disease","Acute Pancreatitis","Chronic Pancreatitis","Hereditary Pancreatitis","Pancreatic Neuroendocrine Carcinoma","Pancreatic Adenocarcinoma",[34,35,36,37,38,39,40,41,42,43],"recurrent pancreatic cancer","stage I pancreatic cancer","stage II pancreatic cancer","stage III pancreatic cancer","stage IV pancreatic cancer","recurrent islet cell carcinoma","pancreatic alpha cell carcinoma","pancreatic beta islet cell carcinoma","pancreatic delta cell carcinoma","pancreatic G-cell carcinoma","RECRUITING","2026-03-05",{"date":47,"type":48},"2026-03-09","ACTUAL",{"date":50,"type":48},"2000-10-01",{"date":52,"type":20},"2027-08-30",{"name":54,"class":55},"Mayo Clinic","OTHER",3,{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":64,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100624699","french-national-cohort-of-patients-with-prss1-mutations-100624699","NCT07413029","French National Cohort of Patients With PRSS1 Mutations","PARADISIO 1","Inclusion Criteria:\n\n* Being a carrier of a known genetic mutation in the PRSS1 gene coding for cationic trypsinogen\n* Be followed in one of the participating centers\n\nExclusion Criteria:\n\n* Opposition to data collection, expressed by the patient or one of their legal representatives",{"count":65,"type":20},800,"The diagnosis of hereditary pancreatitis (PH) is based on a genetic criterion - detection of a mutation in the PRSS1 gene or on a genealogical criterion - the presence of chronic pancreatitis in at least 2 first-degree relatives or at least 3 relatives in the second degree, in the absence of other identified predisposing factors (notably chronic alcohol consumption). It is now recommended to seek PH in cases of pancreatitis of unknown origin in a young patient or with a family history.\n\nIn this study, patients carrying a PRSS1 mutation will be identified from the patient lists of the three French genetics laboratories (Brest University Hospital, Cochin-Paris University Hospital, Lille University Hospital) carrying out PRSS1 gene analysis. Patients will be included by the doctors currently treating them.\n\nThe aim of the study is to assess the incidence of pancreatic adenocarcinoma in the cohort and describe the natural history of hereditary pancreatitis linked to a mutation in PRSS1.",[30,68],"PRSS1 Gene Mutation",[70],"hereditary pancreatitis, mutation","2026-02-09",{"date":73,"type":48},"2026-02-17",{"date":75,"type":48},"2024-11-10",{"date":77,"type":20},"2044-12-31",{"name":79,"class":55},"Assistance Publique - Hôpitaux de Paris",1,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":93,"conditions":94,"keywords":98,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":80},"100419573","artificial-intelligence-based-early-screening-of-pancreatic-cancer-and-high-risk-tracing-esprit-ai-100419573","NCT04743479","Artificial Intelligence-based Early Screening of Pancreatic Cancer and High Risk Tracing (ESPRIT-AI)","Artificial Intelligence-based Health Information Management System and Key Technology Study of Early Screening and Hierarchical Diagnosis and Treatment of Pancreatic Cancer","ESPRIT-AI","Inclusion Criteria:\n\n* Subject is able and willing to provide informed consent and sign an informed consent form.\n* Subject or authorized representative must be willing to complete a detailed questionnaire.\n* Subject must meet one of the following criteria:\n\n  1. New onset diabetes (diagnosed within the past 3 years)\n  2. Familial pancreatic cancer\n  3. Inherited syndromes associated with pancreatic cancer (including Hereditary pancreatitis, Familial atypical multiple mole and melanoma syndrome, Hereditary nonpolyposis colon cancer, Peutz-Jeghers syndrome, Hereditary breast and ovarian cancer syndromes, etc)\n  4. Pancreatic cystic neoplasm (including IPMN, MCN)\n  5. Chronic pancreatitis\n\nExclusion Criteria:\n\n* Subject has been diagnosed with pancreatic cancer or other malignant tumors in the last 5 years;\n* Subject has any medical condition that contraindicates high-resolution MRI or CT;\n* Subject cannot be followed up or is participating in other clinical trials.","50 Years","75 Years",{"count":92,"type":20},5000,"Pancreatic cancer is one of the most fatal malignancies with a 5-year survival rate of only \\~6%\\[1\\]. The reasons for this high mortality rate can be attributed to several factors, of which perhaps the most important is delayed diagnosis due to vague symptoms and consequently missed opportunities for surgical resection. Therefore, the ability to detect pancreatic cancer at an early, more curable stage is urgently needed.\n\nIdentifying risk factors and biomarkers of early pancreatic cancer could facilitate screening for individuals at higher than average risk and expedite the diagnosis in individuals with symptoms and substantially improve an individual's chance of surviving the disease. Thus, the investigators propose this longitudinal study entitled, \"Artificial Intelligence-based Early Screening of Pancreatic Cancer and High Risk Tracing (ESPRIT-AI)\" in order to generate clinical data sets and bank serial blood specimens of high risk individuals.",[26,95,96,97,29,30],"Diabetes","Familial Pancreatic Cancer","Pancreatic Cystic Neoplasm",[99,100,101,26],"Screening","Early Diagnosis","Artificial Intelligence","2023-08-31",{"date":104,"type":48},"2023-09-01",{"date":106,"type":48},"2020-12-01",{"date":108,"type":20},"2030-12-30",{"name":110,"class":55},"Changhai Hospital",{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":122,"conditions":123,"keywords":129,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":5},"100369811","registry-of-subjects-at-risk-of-pancreatic-cancer-100369811","NCT04095195","Registry of Subjects at Risk of Pancreatic Cancer","Italian Registry of Families At Risk of Pancreatic Cancer","IRFARPC","Inclusion Criteria to enter the registry:\n\n* individuals with at least two relatives suffering from pancreatic cancer, with at least 1 first-degree and until the third-degree\n* subjects with known genetic mutation of BRCA2, BRCA1, p16, PALB2 with at least 1 first- or 2nd-degree relative suffering from pancreatic cancer\n* subjects suffering from FAMMM Syndrome\n* subjects suffering from Peutz-Jeghers Syndrome\n* subjects suffering from PRSS-1- or CFTR- or SPINK-1- related pancreatitis\n* subjects suffering from Lynch syndrome with at least 1 first- or 2nd-degree relative suffering from pancreatic cancer\n\nInclusion criteria to join the \"radiologic follow-up\":\n\n* 45 years or 10 years younger than the youngest index case of pancreatic cancer in the family for familial cases\n* 40 years or 5 years younger than the youngest index case of pancreatic cancer for subjects suffering from hereditary\u002Fgenetic pancreatitis, Lynch syndrome, or carrying a known BRCA 1\u002F2, PALB2, p16 genetic mutation with familiarity for pancreatic cancer\n* 30 years for subjects suffering from FAMMM, Peutz-Jeghers syndrome\n\nExclusion Criteria:\n\n\\- pregnancy","80 Years",{"count":121,"type":20},1000,"IRFARPC is a multicenter national registry designed to study the diagnosis and predisposing factors of subjects with an inherited increased risk for pancreatic cancer.",[96,124,125,126,127,30,128],"BRCA1 Mutation","BRCA2 Mutation","Lynch Syndrome","FAMMM - Familial Atypical Mole Malignant Melanoma Syndrome","Peutz-Jeghers Syndrome",[96,130,126,131,132],"BRCA Mutation","Screening pancreatic cancer","Surveillance pancreatic cancer","2023-01-12",{"date":135,"type":48},"2023-01-13",{"date":137,"type":48},"2019-08-20",{"date":139,"type":20},"2045-09-20",{"name":141,"class":55},"Associazione Italiana per lo Studio del Pancreas"]